Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples